Sensus Healthcare, Inc. SRTS
its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, "Sensus,"
"we," "us," "our," or the "Company") is a medical device company committed to providing
highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company
uses a proprietary low-energy X-ray technology known as superficial radiation therapy ("SRT"), which is based on decades
Last close
3.19
2026-09-04
Market cap
$52.5M
2026-06-30 share count
52-week range
2.66 - 5.49
Valuation FY2025 figures against the last close
P/S1.9x
P/E—
P/FCF158.2x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.47
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $41.8M | $24.4M | $44.5M | $27.0M | $9.6M | $27.3M | $26.4M | $20.6M | $14.8M |
| Cost of revenue | $15.6M | $17.4M | $10.3M | $14.9M | $10.1M | $4.3M | $9.7M | $9.5M | $6.8M | $5.0M |
| Gross profit | $11.9M | $24.4M | $14.1M | $29.6M | $17.0M | $5.2M | $17.6M | $16.9M | $13.8M | $9.8M |
| R&D | $7.8M | $4.2M | $3.7M | $3.5M | $3.4M | $4.2M | $6.4M | $6.3M | $5.5M | $1.8M |
| SG&A | $7.9M | $7.1M | $5.2M | $5.0M | $4.6M | $4.0M | $4.0M | $4.1M | $3.7M | $3.5M |
| Total operating expenses | $22.2M | $16.3M | $14.4M | $14.8M | $12.9M | $13.5M | $19.5M | $18.9M | $17.5M | $10.2M |
| Operating income | -$10.3M | $8.1M | -$382.0K | $14.8M | $4.1M | -$8.2M | -$2.0M | -$2.0M | -$3.7M | -$363.1K |
| Interest expense | $683.0K | $932.0K | $992.0K | $380.0K | $2.0K | $14.0K | — | $156.7K | $68.9K | $21.9K |
| Pre-tax income | -$9.6M | $9.0M | $652.0K | $28.0M | $4.1M | — | — | — | — | -$346.4K |
| Income tax | $1.9M | $2.4M | $167.0K | $3.7M | — | — | — | — | — | — |
| Net income | -$7.7M | $6.6M | $485.0K | $24.2M | $4.1M | -$6.8M | -$1.7M | -$2.0M | -$3.7M | -$346.4K |
| EPS, basic | -0.47 | 0.41 | 0.03 | 1.47 | 0.25 | -0.42 | — | — | — | — |
| EPS, diluted | -0.47 | 0.41 | 0.03 | 1.46 | 0.25 | -0.42 | -0.10 | -0.14 | -0.28 | -0.03 |
| Shares, diluted (wtd. avg.) | $16.3M | $16.4M | $16.3M | $16.6M | $16.5M | $16.4M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $22.1M | $22.1M | $23.1M | $25.5M | $14.5M | $14.9M | $8.1M | $12.5M | $10.1M | $5.0M |
| Receivables | $6.0M | $19.7M | $10.6M | $17.3M | $12.1M | $3.8M | $14.0M | $13.1M | $5.0M | $3.1M |
| Inventory | $14.6M | $10.1M | $11.9M | $3.5M | $1.8M | $4.4M | $3.0M | $1.6M | $1.2M | $1.3M |
| Total current assets | $45.9M | $56.7M | $49.5M | $53.2M | $31.2M | $25.2M | $34.0M | $31.9M | $17.9M | $16.8M |
| Property, plant and equipment | $2.0M | $2.0M | $464.0K | $243.0K | $605.0K | $257.0K | $1.1M | $891.0K | $394.1K | $433.4K |
| Other intangibles | — | — | — | $50.0K | $146.0K | $338.0K | $337.0K | $433.7K | $530.1K | $626.5K |
| Total assets | $53.0M | $62.2M | $53.7M | $56.7M | $32.2M | $28.0M | $36.9M | $33.3M | $18.8M | $18.9M |
| Accounts payable | $3.3M | $4.8M | $2.8M | $5.5M | $4.1M | $2.9M | $4.8M | $5.2M | $4.1M | $2.8M |
| Total current liabilities | $4.7M | $5.9M | $4.2M | $7.7M | $6.0M | $4.9M | $6.5M | $6.0M | $4.9M | $3.7M |
| Total liabilities | $4.9M | $6.3M | $4.9M | $8.7M | $6.2M | $6.5M | $8.9M | $6.8M | $7.2M | $3.7M |
| Retained earnings | $5.7M | $13.4M | $6.8M | $6.3M | -$17.9M | -$22.1M | -$15.2M | -$13.5M | -$11.5M | -$7.8M |
| Total equity | $48.1M | $55.8M | $48.8M | $48.1M | $26.0M | $21.5M | $28.0M | $26.5M | $11.7M | $15.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $528.0K | -$831.0K | -$2.1M | -$1.4M | -$286.0K | -$434.0K | -$2.1M | -$8.6M | -$3.1M | -$851.0K |
| Depreciation and amortisation | $386.0K | $239.0K | $200.0K | $219.0K | $613.0K | $722.0K | $545.7K | $658.3K | $387.9K | $337.6K |
| Stock-based compensation | $295.0K | $323.0K | $328.0K | $187.0K | $415.0K | $386.0K | $620.9K | $982.6K | $405.9K | $726.4K |
| Capital expenditure | $196.0K | $276.0K | $229.0K | $159.0K | $128.0K | $359.0K | $400.6K | $854.8K | $287.6K | $286.0K |
| Investing cash flow | -$196.0K | -$276.0K | -$187.0K | $14.8M | $129.0K | $7.0M | -$4.9M | -$2.6M | $6.2M | -$7.9M |
| Financing cash flow | -$305.0K | $15.0K | -$40.0K | -$2.4M | -$231.0K | $211.0K | $2.6M | $13.6M | $1.9M | $8.7M |
| Buybacks | $300.0K | — | $27.0K | $3.0M | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001753926-26-000435.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |